ClinicalTrials.gg
CompletedNCT06713499Updated Jul 2, 2026

A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

A Phase 1/2 interventional study of SHR-1819 injection in Children and Adolescents With Moderate-to-severe Atopic Dermatitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 2 sites in China. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
13th of 14
51 · median 159
Started
2024
with 1 other
Phase 1/2
Only one
of the 14
Registered
8th of 14
by date

Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 13th largest by enrollment, is one of 2 that started in 2024, is the only one in phase 1/2, and was the 8th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.

03

Conditions studied

  • Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects and their parents or legal guardians have voluntarily signed the form prior to the start of any procedures related to the study, are able to communicate smoothly with the investigator, understand and are willing to strictly comply with the requirements of this clinical study protocol to complete the study;
  2. At the time of signing the informed consent, the subjects were ≥ 6 years old and \< 18 years old, male or female;
  3. Have atopic dermatitis at screening.

Exclusion criteria

Exclusion Criteria:

  1. Before enrollment, the subjects weighed \< 15kg;
  2. Females who are pregnant or lactating and have a positive pregnancy test result;
  3. Have other active skin disease or skin complications due to other conditions that may affect the evaluation of AD;
  4. Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial;
  5. Treated with biologics targeting IL-4Rα , or participated in previous clinical studies of biologics targeting IL-4Rα, including SHR-1819 injection;
  6. Has or has a history of malignancy;
  7. to the study drug or any ingredient in the study drug.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    SHR-1819 injection

    Dose 1, dose 2 and dose 3.

    Drug: SHR-1819 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Up to 14 weeks.

  2. Heart rate

    Time frame: Up to 14 weeks.

  3. PR interval

    Time frame: Up to 14 weeks.

  4. QT interval

    Time frame: Up to 14 weeks.

  5. QRS duration

    Time frame: Up to 14 weeks.

Secondary outcomes

  1. The concentration of SHR-1819 in serum

    Time frame: From the beginning of administration to the 14th week.

  2. Changes in the level of TARC/CCL17 in the serum

    Changes in the level of biomarkers in serum.

    Time frame: From the beginning of administration to the 14th week.

  3. Evaluate the incidence and timing of ADA positivity for SHR-1819

    Changes in the level of immunogenicity in the body.

    Time frame: From the beginning of administration to the 14th week.

07

Study locations

2 sites
  • Beijing Children's Hospital, Capital Medical University
    Beijing, Beijing Municipality 100045, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110002, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Nov 2025, 11 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 11 months is below that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2024
First posted
Dec 3, 2024
StartActual
Dec 18, 2024
Primary completionActual
Nov 22, 2025
CompletionActual
Nov 22, 2025
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06713499
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Dec 18, 2024
Primary completion
Nov 22, 2025
Completion
Nov 22, 2025
Last update
Jul 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drotokibart

Start the discussion